查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654430

单核细胞活化分析市场规模、份额、趋势分析报告：按产品、来源、最终用途、地区和细分市场进行预测，2025 年至 2030 年

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

单核细胞活化试验 (MAT) 市场成长与趋势

根据Grand View Research, Inc.的最新报告，全球单核细胞活化测试市场规模预计到2030年将达到14.5亿美元，2025年至2030年期间的复合年增长率为15.9%。

市场受到几个关键因素的驱动。越来越大的监管压力要求以更符合道德、更适合人类的体外方法取代动物试验，这是一个主要驱动因素。 MAT 利用人体免疫细胞进行精确的热原检测能力使其成为传统内毒素检测的一种有吸引力的替代方案。对生技药品、疫苗和复杂药物的需求不断增长，进一步推动了 MAT 的采用，因为这些产品的安全性至关重要。此外，生物技术的进步以及对病人安全和药物开发品管的日益重视也促进了市场的成长。

技术创新正在推动单核细胞活化测试市场的成长。其中一个重大进展是创建更有效率、更可重复的细胞培养系统，特别是使用永生化人类细胞株，如 THP-1 和 U937 细胞。这些细胞株提高了 MAT 的精确度和一致性，使其成为传统动物测试方法的更可靠替代方案。使用这些细胞株模拟人体免疫反应的能力提高了 MAT 的灵敏度，从而可以更好地检测热原（包括内毒素和非内毒素）。

另一项创新是 MAT 流程的自动化，它简化了测试工作流程并减少了获得结果所需的时间。 MAT 样品製备和分析的自动化系统正在提高吞吐量，使得大型製药和生物技术公司更有能力将 MAT 纳入其品管流程。 Minerva Biolabs 的下一代 MAT 系统 N​​AT-MAT​​ 代表了热原测试的重大进步。透过利用数位 PCR 测量 IL-1B 和 TNF-a 的基因表现，NAT-MAT​​ 对检测内毒性和非内毒性热原提供了高度灵敏和可靠的结果。该系统针对快速测试进行了最佳化，并符合 Ph. Eur. 2.6.30 标准。

NAT-MAT​​® 的关键创新是同时测量两种细胞激素和管家基因，从而提高结果的准确性。管家基因作为萃取过程和细胞密度的品管，以确保该检测在不同细胞密度下可靠地进行。此外，使用 Minerva Biolabs 专有软体进行自动分析可简化流程并提高测试效率，同时确保符合法规要求。

该技术比传统的热原检测方法有了显着的改进，提供了更全面、更准确的方法来确保药品和生物技术产品的安全。例如，Lonza Group 和 Charles River Laboratories 等公司正在将先进的细胞培养技术和自动化系统整合到其 MAT 产品中，以提高效率和可扩展性。此外，高通量和筛检技术的进步使得热原检测更快、更具成本效益，使 MAT 在药物开发和疫苗製造中得到更广泛的应用。这些创新持续促进 MAT 的广泛使用，使其成为确保药品和生技产品安全性和有效性的重要工具。

单核细胞活化测试市场报告重点

  • 按产品划分，MAT套件部门在 2024 年占据最大的收入份额，为 63.7%。由于对可靠的人体相关热原检测方法的需求不断增加，MAT套件领域正在经历成长。一个主要的驱动因素是不断增加的监管压力，要求用试管内试验取代动物试验。 MAT套件利用人体免疫细胞检测内毒素和非内毒素热原，提供了准确、道德的解决方案，确保药物安全。此外，生技药品、疫苗和复杂药物製剂的日益普及也推动了对 MAT套件的需求。这些产品必须经过严格的安全测试才能进入市场。 MAT套件的便利性和准确性进一步促进了其被采用。
  • 作为动物试验的替代品，对符合道德的人体试验的需求不断增长，导致 PBMC 占据了市场主导地位，到 2024 年占据 62.7% 的最大份额。 PBMCs 含有单核细胞，对于热原检测至关重要，因为它们与人类的免疫反应非常相似。这种与人类相关的测试方法正在获得支持，因为与传统动物模型相比，它可以提供更准确和可重复的结果。此外，生技药品的发展、疫苗可用性的增加以及用试管内方法取代动物测试的监管压力进一步推动了基于 PBMC 的 MAT 测试的采用。
  • 根据应用，由于对准确可靠的热原检测方法的需求不断增加，药物开发将占据市场主导地位，到 2024 年将占据 40.6% 的最大份额。随着製药业开发出更复杂的生技药品和疫苗，透过严格的测试确保这些产品的安全至关重要。 MAT 描述了一种体外、与人类相关的检测内毒素和非内毒素热原的方法，取代了传统的动物测试方法。 FDA 和 EMA 等监管机构已核准MAT 作为有效的替代方案，进一步鼓励其在药物开发中的应用。越来越关注病人安全、法规遵循和对更快测试方法的需求是关键驱动因素。
  • 根据最终用途，製药业将在 2024 年占据最大的市场占有率，达到 56.3%。市场成长的驱动力是药品开发和製造过程中对可靠的热原测试的日益增长的需求。由于该行业专注于生产生技药品、疫苗和其他复杂的治疗产品，因此确保它们的安全至关重要。 MAT 可使用人体免疫细胞检测内毒素和非内毒素热原，是一种准确且合乎道德的传统动物测试替代方法。 FDA 和 EMA 等监管机构支持使用 MAT 并鼓励其采用。製药製造业对更安全、更快捷、更有效的测试方法的需求日益增长，是推动 MAT 市场成长的主要因素。
  • 北美在全球市场占据主导地位的关键因素是该地区严格的法规环境，FDA 和加拿大卫生署等机构越来越多地支持 MAT 作为传统动物试验的可靠且合乎道德的替代方案。生技药品和疫苗领域的成长也推动了对 MAT 的需求，因为确保产品安全至关重要。此外，对病人安全的日益关注、生物技术的进步以及对更高效和更适合人类的热原检测方法的需求，促使 MAT 在北美得到广泛采用。
  • 预计亚太地区将成长最快，预测期内 2025-2030 年的复合年增长率为 17.3%，製药和生物技术领域将快速进步。这在很大程度上是由于中国、日本和印度等国家对生技药品、疫苗和联合疗法的需求不断增长。这些国家的监管机构越来越多地采用 MAT 作为传统动物试验的首选替代方案，以符合全球道德标准。此外，对病人安全的日益关注以及对更高效、更人性化的检测方法的需求正在推动 MAT 的采用。该地区不断扩大的医疗保健基础设施进一步支持了 MAT 不断增长的市场影响。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章单核细胞活化测试市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 单核细胞活化测试市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析
    • 定价分析

第 4 章单核细胞活化测试市场：产品、估计与趋势分析

  • 全球单核细胞活化测试市场：产品仪表板
  • 全球单核细胞活化测试市场：产品变异分析
  • 全球单核细胞活化测试市场（按产品和收益）
  • 单核细胞活化检测套件
  • 试剂

第 5 章 单核细胞活化测试市场：按应用进行的估计和趋势分析

  • 全球单核细胞活化测试市场：应用仪表板
  • 全球单核细胞活化测试市场：应用趋势分析
  • 全球单核细胞活化测试市场（按应用和收益）
  • 药物开发
  • 疫苗研发
  • 医疗设备测试
  • 其他的

第六章 单核球活化测试市场来源、估计与趋势分析

  • 全球单核细胞活化测试市场：来源仪表板
  • 全球单核细胞活化测试市场：来源变异分析
  • 全球单核细胞活化测试市场（依来源、收益）
  • 基于PBMC
  • 基于细胞株

7. 单核球活化测试市场：最终用途、估计与趋势分析

  • 全球单核细胞活化测试市场：最终用途仪表板
  • 全球单核细胞活化测试市场：最终用途变异分析
  • 全球单核细胞活化测试市场（按最终用途和收益）
  • 製药业
  • 生技产业
  • 医疗设备业
  • 其他的

第 8 章单核细胞活化测试市场按产品、来源、应用、最终用途、区域、估计和趋势分析

  • 区域控制面板
  • 市场规模、预测趋势分析，2018-2030
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商及通路伙伴名单
    • 2024 年主要企业的市场占有率分析
    • Lonza Group
    • Charles River Laboratories
    • Bio-Rad Laboratories
    • Seikagaku Corporation
    • Hyglos GmbH
    • Hyglos GmbH
    • Thermo Fisher Scientific
    • MAT BioTech
    • Eurofins Scientific
Product Code: GVR-4-68040-510-0

Monocyte Activation Test Market Growth & Trends:

The global monocyte activation test market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 15.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. Increasing regulatory pressure to replace animal testing with more ethical, human-relevant in vitro methods is a major driver. MAT's ability to provide accurate pyrogen detection using human immune cells makes it an attractive alternative to traditional endotoxin tests. The growing demand for biologics, vaccines, and complex pharmaceuticals further fuels MAT adoption, as safety is critical in these products. Additionally, advancements in biotechnology and the increasing emphasis on patient safety and quality control in drug development are contributing to the market's growth.

Technological innovations are significantly driving the growth of the Monocyte Activation Test (MAT) market. One of the key advancements is the development of more efficient and reproducible cell culture systems, particularly the use of immortalized human cell lines like THP-1 and U937 cells. These cell lines enhance the accuracy and consistency of MAT, making it a more reliable alternative to traditional animal testing methods. The ability to simulate the human immune response with these cell lines has improved the sensitivity of MAT, allowing for better detection of pyrogens, including both endotoxins and non-endotoxins.

Another innovation is the automation of MAT processes, which has streamlined testing workflows and reduced the time required to obtain results. Automated systems for preparing and analyzing MAT samples have increased throughput, making it more feasible for large-scale pharmaceutical and biotechnology companies to incorporate MAT into their quality control processes. Minerva Biolabs' next-generation MAT system, the NAT-MAT, represents a significant advancement in pyrogen testing. By utilizing digital PCR to measure the gene expression of IL-1B and TNF-a, the NAT-MAT provides highly sensitive and reliable results for detecting both endotoxin and non-endotoxin pyrogens. This system is optimized for fast testing, making it suitable for in-process control and final release testing of medicinal products, in line with Ph. Eur. 2.6.30 standards.

The key innovation in the NAT-MAT(R) lies in the parallel measurement of two cytokines alongside a housekeeping gene, which improves the accuracy of results. The housekeeping gene serves a dual purpose: it acts as a quality control for both the extraction process and cell density, ensuring the assay functions reliably across different cell densities. Additionally, the automated analysis through Minerva Biolabs' specialized software streamlines the process, ensuring compliance with regulatory requirements while enhancing testing efficiency.

This technology provides a significant improvement over traditional pyrogen testing methods by offering a more comprehensive and precise approach to ensuring the safety of pharmaceutical and biotechnological products. For example, companies like Lonza Group and Charles River Laboratories have integrated advanced cell culture technologies and automated systems into their MAT offerings, improving efficiency and scalability. Furthermore, advancements in high-throughput screening technologies have enabled faster and more cost-effective pyrogen testing, allowing MAT to be used in drug development and vaccine production more widely. These technological innovations continue to enhance MAT's adoption, making it an essential tool for ensuring the safety and efficacy of pharmaceutical and biotechnological products.

Monocyte Activation Test Market Report Highlights:

  • Based on product, MAT Kits segment accounted for largest revenue share of 63.7% in 2024. The MAT Kits segment is experiencing growth due to the increasing demand for reliable, human-relevant pyrogen testing methods. A key driving factor is the growing regulatory pressure to replace animal testing with in vitro alternatives. MAT kits offer a precise and ethical solution by using human immune cells to detect endotoxins and non-endotoxin pyrogens, ensuring the safety of pharmaceutical products. Additionally, the rising prevalence of biologics, vaccines, and complex drug formulations is driving the demand for MAT kits, as these products require stringent safety testing before reaching the market. The convenience and accuracy of MAT kits further boost their adoption.
  • Based on source, PBMC dominated the market and accounted for the largest share of 62.7% in 2024, due to the increasing demand for human-based, ethical alternatives to animal testing. PBMCs, which include monocytes, are critical for detecting pyrogens as they closely mimic the human immune response. This human-relevant testing method is gaining favor due to its ability to provide more accurate and reproducible results compared to traditional animal models. Additionally, the rise in biologic drug development, vaccines, and regulatory pressures to replace animal testing with in vitro methods further drives the adoption of PBMC-based MAT testing.
  • Based on application, drug development dominated the market and accounted for the largest share of 40.6% in 2024, due to increasing demand for accurate and reliable pyrogen testing methods. As the pharmaceutical industry develops more complex biologics and vaccines, ensuring product safety through rigorous testing is crucial. MAT provides an in vitro, human-relevant approach to detect endotoxins and non-endotoxin pyrogens, replacing traditional animal testing methods. Regulatory bodies like the FDA and EMA endorse MAT as a valid alternative, further promoting its adoption in drug development. The growing focus on patient safety, regulatory compliance, and the need for faster testing methods are key driving factors.
  • Based on end use, pharmaceutical industry segment is dominated the end use segments with the largest market share of 56.3% in 2024. The market growth is fueled by factors such as increasing need for reliable pyrogen testing in drug development and manufacturing. As the industry focuses on producing biologics, vaccines, and other complex therapeutic products, ensuring their safety is paramount. MAT, with its ability to detect endotoxins and non-endotoxin pyrogens using human immune cells, provides an accurate and ethical alternative to traditional animal testing. Regulatory agencies like the FDA and EMA support MAT's use, driving its adoption. The growing demand for safer, faster, and more efficient testing methods in pharmaceutical production is a key factor fueling MAT's market growth.
  • North America dominated the global market, primary driver is the region's stringent regulatory environment, with agencies like the FDA and Health Canada increasingly endorsing MAT as a reliable and ethical alternative to traditional animal testing. The demand for MAT is also fueled by the growing biologics and vaccine sectors, where ensuring product safety is crucial. Additionally, the rising focus on patient safety, advancements in biotechnology, and the need for more efficient and human-relevant pyrogen testing methods are contributing to the widespread adoption of MAT in North America.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 17.3% over the forecast period from 2025 to 2030, rapid advancements in the pharmaceutical and biotechnology sectors. The growing demand for biologics, vaccines, and complex therapeutics in countries like China, Japan, and India is a major factor. Regulatory authorities in these countries are increasingly adopting MAT as a preferred alternative to traditional animal testing, aligning with global ethical standards. Additionally, the rising focus on patient safety and the need for more efficient, human-relevant testing methods are driving MAT adoption. The region's expanding healthcare infrastructure further supports MAT's growing market presence.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Source
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and source outlook
    • 2.2.2. Application and end use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Monocyte activation test (MAT) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing demand for safer and more accurate alternatives to LAL (Limulus Amebocyte Lysate) test
      • 3.2.1.2. Rising regulatory requirements for medical devices and pharmaceuticals
      • 3.2.1.3. Growing adoption of in vitro testing methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High initial setup costs
      • 3.2.2.2. Limited standardization and adoption across all regulatory frameworks
  • 3.3. Monocyte activation test (MAT) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Monocyte activation test (MAT) Market: Product Estimates & Trend Analysis

  • 4.1. Global Monocyte activation test (MAT) Market: Product Dashboard
  • 4.2. Global Monocyte activation test (MAT) Market: Product Movement Analysis
  • 4.3. Global Monocyte activation test (MAT) Market by Product, Revenue
  • 4.4. MAT Kits
    • 4.4.1. MAT kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents
    • 4.5.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Monocyte activation test (MAT) Market: Application Estimates & Trend Analysis

  • 5.1. Global Monocyte activation test (MAT) Market: Application Dashboard
  • 5.2. Global Monocyte activation test (MAT) Market: Application Movement Analysis
  • 5.3. Global Monocyte activation test (MAT) Market by Application , Revenue
  • 5.4. Drug Development
    • 5.4.1. Drug Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Vaccine Development
    • 5.5.1. Vaccine Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Medical Device Testing
    • 5.6.1. Medical Device Testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Monocyte activation test (MAT) Market: Source Estimates & Trend Analysis

  • 6.1. Global Monocyte activation test (MAT) Market: Source Dashboard
  • 6.2. Global Monocyte activation test (MAT) Market: Source Movement Analysis
  • 6.3. Global Monocyte activation test (MAT) Market by Source, Revenue
  • 6.4. PBMC Based
    • 6.4.1. PBMC Based market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Cell Line Based
    • 6.5.1. Cell Line Based market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Monocyte activation test (MAT) Market: End use Estimates & Trend Analysis

  • 7.1. Global Monocyte activation test (MAT) Market: End use Dashboard
  • 7.2. Global Monocyte activation test (MAT) Market: End use Movement Analysis
  • 7.3. Global Monocyte activation test (MAT) Market by End use, Revenue
  • 7.4. Pharmaceutical Industry
    • 7.4.1. Pharmaceutical Industry market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Biotechnology Industry
    • 7.5.1. Biotechnology Industry market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Medical Device Industry
    • 7.6.1. Medical Device Industry Analysis market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Monocyte activation test (MAT) Market: Regional Estimates & Trend Analysis by Product, Source, Application and Methodology

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Lonza Group
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Charles River Laboratories
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Seikagaku Corporation
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Hyglos GmbH
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Hyglos GmbH
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. MAT BioTech
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Eurofins Scientific
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 8 U.S. Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 9 U.S. Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 13 Canada Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 14 Canada Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 17 Mexico Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 22 Europe Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 23 Europe Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 25 Germany Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 26 Germany Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 27 Germany Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 29 UK Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 30 UK Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 31 UK Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 33 France Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 34 France Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 35 France Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 37 Italy Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 38 Italy Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 39 Italy Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 41 Spain Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 42 Spain Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 43 Spain Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 45 Denmark Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 46 Denmark Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 47 Denmark Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 49 Sweden Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 50 Sweden Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 51 Sweden Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 53 Norway Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 54 Norway Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 55 Norway Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 60 Aisa Pacific Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 62 China Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 63 China Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 64 China Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 66 Japan Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 67 Japan Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 68 Japan Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 70 India Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 71 India Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 72 India Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 74 South Korea Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 75 South Korea Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 76 South Korea Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 78 Australia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 79 Australia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 80 Australia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 82 Thailand Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 83 Thailand Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 84 Thailand Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 87 Latin America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 88 Latin America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 89 Latin America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 91 Brazil Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 92 Brazil Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 93 Brazil Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 96 Argentina Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 97 Argentina Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 100 MEA Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 101 MEA Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 102 MEA Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 105 South Africa Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 106 South Africa Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 113 UAE Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 114 UAE Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Monocyte activation test (MAT) market: market outlook
  • Fig. 14 Monocyte activation test (MAT) competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Monocyte activation test (MAT) market driver impact
  • Fig. 18 Monocyte activation test (MAT) market restraint impact
  • Fig. 19 Monocyte activation test (MAT) market: Product movement analysis
  • Fig. 20 Monocyte activation test (MAT) market: Product outlook and key takeaways
  • Fig. 21 MAT Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Monocyte activation test (MAT) market: Application movement analysis
  • Fig. 24 Monocyte activation test (MAT) market: Application outlook and key takeaways
  • Fig. 25 Drug Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Vaccine Development estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Medical Device Testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Monocyte activation test (MAT) market: Source movement analysis
  • Fig. 30 Monocyte activation test (MAT) market: Source outlook and key takeaways
  • Fig. 31 PBMC Based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Cell Line Based estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Monocyte activation test (MAT) market: End use movement analysis
  • Fig. 34 Monocyte activation test (MAT) market: End use outlook and key takeaways
  • Fig. 35 Pharmaceutical Industry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Biotechnology Industry estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Medical Device Industry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Monocyte activation test (MAT) market: Regional movement analysis
  • Fig. 40 Global Monocyte activation test (MAT) market: Regional outlook and key takeaways
  • Fig. 41 Global Monocyte activation test (MAT) market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- Monocyte activation test (MAT) market